Abstract
Aim:
The aim of the present study was to further improve the therapeutic effects for human hepatocellular carcinoma (HCC) and reduce the damage in normal cells using a novel chemo-gene-virotherapeutic strategy.
Methods:
An oncolytic adenoviral vector (ZD55) similar to the typical oncolytic adenovirus ONYX-015, with a deletion of E1B-55K gene, was employed to express the second mitochondria-derived activator of caspases (Smac) protein by constructing a recombinant virus ZD55-Smac. The enhanced cytotoxicity of the combined treatment of ZD55-Smac with cisplatin or 5-fluorouracil (5-FU) was evaluated in several HCC cell lines. Moreover, the negative effects on normal cells have been tested in human normal liver cell lines L-02 and QSG-7701 cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and apoptotic cell staining.
Results:
According to our observation, ZD55-Smac is superior to ONYX-015 in sensitizing chemotherapy, ZD55-Smac used in conjunction with chemotherapy was found to exhibit obviously enhanced cytotoxicity in HCC cells, yet significantly abolished the negative toxicity in normal cells by utilizing the tumor selective replication vector and reducing the dosage.
Conclusion:
This chemo-gene-virotherapeutic (cisplatin or 5-FU+ZD55-Smac) strategy is superior to the conventional chemo-gene or chemo-viro approach.
Similar content being viewed by others
Article PDF
References
Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620–8.
Shimada M, Takenaka K, Kawahara N, Yamamoto K, Shirabe K, Maehara Y, et al. Chemosensitivity in primary liver cancers: evaluation of the correlation between chemosensitivity and clinicopathological factors. Hepatogastroenterology 1996; 43: 1159–64.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421–30.
Deveraux QL, Reed JC . IAP family proteins — suppressors of apoptosis. Genes Dev 1999; 13: 239–52.
Chai J, Shiozaki E, Srinivasula SM, Wu Q, Dataa P, Alnemri ES, et al. Structural basis of caspase-7 inhibition by XIAP. Cell 2001; 104: 769–80.
Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R . X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J Biol Chem 2001; 276: 27 058–63.
Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81: 824–31.
Nomura T, Yamasaki M, Nomura Y, Mimata H . Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005; 14: 993–7.
Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408: 1008–12.
Srinivasula S, Hegde R, Saleh A, Dattap, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/ DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112–6.
Chai J, Du C, Wu J, Kyin S, Wang X, Shi Y . Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406: 855–62.
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10: 958–66.
Kirn D, Hermiston T, McCormick F . ONYX-015. Clinical data are encouraging. Nat Med 1998; 4: 1341–2.
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluo-rouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–85.
Heise C, Sampson-Johannes A, Williams A, McCormick F, von Hoff DD, Kirn DH . ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639–45.
Wang J, Gu JF, Yang SY, Xiao T, Qi R, Sun LY, et al. Security of dual cancer-specific targeting vector and its cytotoxic effect when harbored. Ai Zheng 2006; 25: 385–92.
Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371–81.
Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/ IL-24 for colorectal cancer. Hum Gene Ther 2005; 16: 845–58.
Kerr JF, Wyllie AH, Currie AR . Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–57.
Fisher DE . Apoptosis in cancer therapy: Crossing the threshold. Cell 1994; 78: 539–42.
Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC . The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16: 6914–25.
Deveraux QL, Takahashi R, Salvesen GS, Reed JC . X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300–4.
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC . Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999; 18: 5242–51.
Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9: 2826–36.
Tu S P, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003; 63: 7724–32.
Chen J, Xiao XQ, Deng CM, Su XS, Li GY . Downregulation of XIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2. J Chemother 2006; 18: 525–31.
Zobel K, Wang L, Varfolomeev E, Franklin MC, Elliott LO, Wallweber HJ, et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006; 1: 525–33.
Galluzzi L, Larochette N, Zamzami N, Kroemer G . Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006; 25: 4812–30.
Wang D, Lippard SJ . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307–20.
Okamura M, Hashimoto K, Shimada J, Sakagami H . Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines. Anticancer Res 2004; 24: 655–61.
Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891–7.
Li YX, Lin ZB, Tan HR . Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/ 5-FU cells. Acta Pharmacol Sin 2004; 25: 76–82.
Author information
Authors and Affiliations
Corresponding authors
Additional information
This work was supported by the 973 Project (No 2004CB518804), the 863 project (No 20060102Z1107), the Zhejiang Provincial Grant (No 2006C23006), Zhejiang Funds for the Returned Students (No 116153A4I0538), and Zhejiang Natural Science Funds (No Y205282).
Rights and permissions
About this article
Cite this article
Pan, Qw., Zhong, Sy., Liu, Bs. et al. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacol Sin 28, 1996–2004 (2007). https://doi.org/10.1111/j.1745-7254.2007.00672.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00672.x
Keywords
This article is cited by
-
Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells
Apoptosis (2016)
-
Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin
Journal of Cancer Research and Clinical Oncology (2015)
-
SMAC-armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC
Human Cell (2014)
-
Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression
Cancer Gene Therapy (2012)
-
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation
Acta Pharmacologica Sinica (2010)